Pharmacoelectrophysiology of Viral-Free Induced Pluripotent Stem

Development of pharmaceutical agents for cardiac indication demands elaborate safety screening in which assessing repolari-zation of cardiac cells remains a critical path in risk evaluations. An efficient platform for evaluating cardiac repolarization in vitro significantly facilitates drug developmental programs. In a proof of principle study, we examined the effect of antiarrhythmogenic drugs (Vaughan Williams class I–IV) and noncardiac active drugs (terfenadine and cisapride) on the repolarization profile of viral-free human-induced pluripotent stem cell-derived cardiomyo-cytes (hiPSC-CMs). Extracellular field potential (FP) recording using microelectrode arrays demonstrated significant delayed repolarization as prolonged corrected FP durations (cFPDs) by class I (quinidine and flecainide), class III (sotalol and amiodar-one), and class IV (verapamil), whereas class II drugs (propran-olol and nadolol) had no effects. Consistent with their sodiu